Opioid abuse has increased in the last decade, primarily as a result of increased access to
prescription opioids. Physicians are also increasingly administering opioid analgesics for …

Aliment Pharmacol Ther 2011; 33: 880–894 Summary Background From a classical point of
view, gastric motility acts to clear the stomach between meals, whereas postprandial motility …

Background Intervention to achieve alcohol abstinence represents the most effective
treatment for alcohol-dependent patients with liver cirrhosis; however, anticraving drugs …

Background and aims Observational studies have yielded conflicting results on the
association of prescription opioid use (POU) with the risk of cardiovascular diseases (CVD) …

Naltrexone is an approved drug for management of alcohol use disorder (AUD), but data in
patients with liver disease (LD) are limited. We aimed to evaluate the safety of naltrexone in …

Existing obesity therapies are limited by safety concerns and modest efficacy reflecting a
weight loss plateau. Here, we explore combination therapy with bupropion (BUP), a putative …

The mechanism of action of the combination therapy, naltrexone/bupropion (NB), for obesity
has not been fully described to date. Weight loss attempts rarely result in long-term success …

A. Peripherally acting agents B. Centrally acting agents IV. Drugs That Alter Metabolism A.
Preabsorptive agents B. Postabsorptive modifiers of nutrient metabolism V. Drugs That …

Synopsis Naltrexone is a long acting competitive antagonist at opioid receptors which blocks
the subjective and objective responses produced by intravenous opioid challenge. It is …

Past therapies for the treatment of obesity have typically involved pharmacological agents
usually in combination with a calorie‐controlled diet. This paper reviews the efficacy and …